EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Stefano Fiorucci iD, Ginevra Urbani, Cristina Di Giorgio, Michele Biagioli iD, Eleonora Distrutti

Cells · 2024

DOI: 10.3390/cells13181580 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Stefano Fiorucci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MUR - Ministero dell'Università e della Ricerca, Italian Ministry of University and Research (MUR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disorder characterized by progressive cholestatic that, if untreated, can progress to liver fibrosis, cirrhosis and liver decompensation requiring liver transplant. Although the pathogenesis of the disease is multifactorial, there is a consensus that individuals with a genetic predisposition develop the disease in the presence of specific environmental triggers. A dysbiosis of intestinal microbiota is increasingly considered among the potential pathogenic factors. Cholangiocytes, the epithelial cells lining the bile ducts, are the main target of a dysregulated immune response, and cholangiocytes senescence has been recognized as a driving mechanism, leading to impaired bile duct function, in disease progression. Bile acids are also recognized as playing an important role, both in disease development and therapy. Thus, while bile acid-based therapies, specifically ursodeoxycholic acid and obeticholic acid, have been the cornerstone of therapy in PBC, novel therapeutic approaches have been developed in recent years. In this review, we will examine published and ongoing clinical trials in PBC, including the recently approved peroxisome-proliferator-activated receptor (PPAR) agonist, elafibranor and seladelpar. These novel second-line therapies are expected to improve therapy in PBC and the development of personalized approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, BiliaryHumansBile Acids and SaltsAnimalsUrsodeoxycholic AcidClinical Trials as TopicChenodeoxycholic Acid

Stichwörter der Autor:innen

T cellscholangiocytescholestasisfarnesoid-x-receptor (FXR)macrophagesperoxisome-proliferator-associated receptors (PPAR)

Substanzen

Bile Acids and SaltsUrsodeoxycholic AcidChenodeoxycholic Acidobeticholic acid

Autor:innen und Institutionen

  • Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy.
  • SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06123 Perugia, Italy.

ORCID-Profile: Stefano Fiorucci, Michele Biagioli

Förderung

  • MUR - Ministero dell'Università e della Ricerca
  • Italian Ministry of University and Research (MUR)

Zitieren

APA

Fiorucci, S., Urbani, G., Di Giorgio, C., Biagioli, M., & Distrutti, E. (2024). Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. Cells. https://doi.org/10.3390/cells13181580

Vancouver

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E. Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. Cells. 2024. doi:10.3390/cells13181580

BibTeX
@article{Fiorucci2024,
  author = {Fiorucci, Stefano and Urbani, Ginevra and Di Giorgio, Cristina and Biagioli, Michele and Distrutti, Eleonora},
  title = {Current Landscape and Evolving Therapies for Primary Biliary Cholangitis},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13181580}
}
Kostenlos starten →